Valve-in-valve Transcatheter Aortic Valve Replacement for Failed Surgical Valves and Adjunctive Therapies

While redo surgical aortic valve replacement has traditionally been the gold standard for treatment of failed valves, valve-in-valve (ViV) transcatheter (TAVR) arisen as a viable, less invasive option with potential improved short-term morbidity and mortality. Retrospective registry data regarding ViV TAVR outcomes have encouraging, excellent 1-year mortality, sustained performance quality life improvement out to 3 years. Operators must be comfortable CT analysis procedural planning, able identify troubleshoot patients who are at risk coronary obstruction patient prosthesis mismatch. The authors provide review clinical associated TAVR, planning recommendations, strategies overcome technical challenges that can occur during TAVR.